ArticleBlood advances2020

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.

Joaquin Martinez-Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.